UNC Medical Center UNC Eshelman School of Pharmacy Durham, North Carolina
Selection of prophylactic anti-fungal agents for oncology patients requires careful consideration of disease state, treatment regimen, and expected duration of neutropenia to avoid therapeutic misadventure. In this session, faculty will review evidence supporting specific antifungal agents along with formulation and PK/PD differences that may influence choice. A variety of risk-mitigation strategies to avoid therapeutic drug-drug interactions will be discussed.
Learning Objectives:
Describe evidence supporting options for anti-fungal prophylaxis in oncology populations.
Identify formulation and PK/PD considerations with anti-fungal options.
Discuss risk-mitigation strategies for potential drug-drug interactions with anti-fungal therapies.
